Congratulations to our winners for August 2018
The ATA Scientific Encouragement Award is hosted four times each year and provides young scientists access to financial assistance to enable them to collaborate with peers at scientific meetings and to launch their careers within their field of study. The topic of our latest competition focused on the strong link between cognitive behaviour and foods. While studies continue to show evidence that supports the idea that food can influence our thought processes, we asked our readers to consider their own experiences and whether particular foods had any influence on their ability to think and concentrate.
After much deliberation, three entries were selected to receive our award– first prize at $1500 and 2 runners up at $600 each.
Congratulations to our first prize winner Samantha Wade, PhD candidate at the Targeted Cancer Therapeutics Laboratory, Illawarra Health and Medical Research Institute, University Of Wollongong, working under the supervision of Dr Kara L. Vine-Perrow.
Congratulations to our runner up, Cameron McKnight. Cameron McKnight is a PhD student based at the Murdoch Children’s Research Institute (MCRI) in the lab of Prof. David Thorburn.
Congratulations to our runner up, Dr Michal Bartnikowski, a Postdoctoral Research Fellow from the School of Dentistry, at The University of Queensland. Michal is currently working with supervisor Professor Sašo Ivanovski on the development of 3D printed scaffolds for bone and periodontal regeneration.
-
Most popular related searches
Related news
-
Creative Proteomics Cytokine Unveils Disease Cytokine Assays for Disease Diagnosis
Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently announced Disease Cytokine Assays to help researchers obtain higher quality scientific research data. Cytokines, including interleukins, interferons, tumor necrosis factors, and chemokines, can play key pro- and anti-inflammatory...
-
SeqOne Genomics closes €20M series A to accelerate the deployment of its genomic medicine platform
The round, led by Omnes, Merieux Equity Partners, together with the Software Club and existing investors, Elaia and IRDI Capital Investissement, will enable SeqOne Genomics to accelerate its international sales and the development of new collaborative genomic analysis tools to facilitate communications between different disciplines in the medical team, in order to improve patient outcomes in cancer and hereditary disease. The company will intensify investments in the development of its genomic-aware data lake to...
-
Profacgen Helps Accelerate GPCR Study with Various Services
Profacgen, a global provider of drug screening and profiling services that offers a comprehensive panel of services designed to speed and simplify drug discovery research, now offers professional high-throughput GPCR screening services for identification of potential GPCR-targeting drugs. G protein-coupled receptors (GPCRs) are also known as seven-transmembrane domain receptors. They are present only in eukaryotes. Because of their extensive involvement in cellular signal transduction, GPCRs have emerged as...
-
Phase III trial with Nubeqa (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
ARASENS trial demonstrates an increase in overall survival evaluating darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) compared to docetaxel and ADT, a standard of care in metastatic hormone-sensitive prostate cancer (mHSPC) / Bayer plans to present these pivotal data at a forthcoming scientific congress and to discuss them with health authorities / ARASENS is part of broad development program for darolutamide which includes another ongoing Phase III trial in mHSPC, ARANOTE,...
-
Creative Proteomics Launches Oncology Multi-omics Platform to Promote Basic Oncology Research
Using its mature multi-omics technology platform, Creative Proteomics has been devoted to providing high-quality, personalized oncology multi-omics services and reliable data support to worldwide clients for years. With the continuous aging of human society, the improvement of industrialization, and the deterioration of the quality of living environment, the incidence of cancer is getting higher and higher. Elucidating the mechanisms of tumorigenesis is utterly dire and a crucial research topic. The use of...
Customer comments
No comments were found for Congratulations to our winners for August 2018. Be the first to comment!